ArticleThe Pediatric infectious disease journal2026
Prevalence of Macrolide-resistant Mycoplasma pneumoniae in Children and Adolescents With Community-acquired Pneumonia: A Prospective Study in Thailand.
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Doxycycline for Macrolide-ResistantInfection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe describe the prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP)-induced pediatric community-acquired pneumonia (CAP) in Bangkok, Thailand.
methodsNasopharyngeal aspirates were prospectively collected from children and adolescents 0-18 years of age with chest radiograph-confirmed CAP between January 2014 and January 2020 at a single tertiary-care center in Bangkok, Thailand. M. pneumoniae was identified from nasopharyngeal aspirates using real-time polymerase chain reaction (RT-PCR). Macrolide-resistant mutations, including A2063G, A2064G, A2067G and C2617G in the 23S rRNA gene, were identified through PCR-sequencing.
resultsOf 332 patients with CAP, 55 (16.6%) had M. pneumoniae infection. Among those with mycoplasmal pneumonia, the median age (range) was 8.3 years (1.2-17.5), and 30 (54.5%) were female. Twenty-five patients (45.5%) developed complications, including 12 (21.8%) cases of pleural effusion, 10 (18.1%) cases of skin rashes, 6 (10.9%) cases of hematologic complications, 2 (3.6%) cases of transaminitis, and 1 (1.8%) case of respiratory failure. Of the 36 patients who underwent genotyping, 8 (22.2%) carried macrolide-resistant mutations-all A2063G mutations. Compared with those without macrolide-resistant mutations, patients with MRMP had a longer time to defervescence after antimicrobial therapy (3.0 vs. 5.5 days, P = 0.003). Patients with and without macrolide-resistant mutations had similar rates of previous exposure to macrolide antibiotics, durations of fever and cough, rates of complications, frequency of oxygen supplementation requirements, lengths of hospitalization and macrolide treatment failure.
conclusionsAbout 1 in 5 children and adolescents with mycoplasmal CAP in Thailand have infections caused by MRMP, which result in a longer time to defervescence after therapy. Monitoring MRMP is crucial to establish local treatment strategies for pediatric CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.